{"id":67335,"date":"2026-06-04T20:07:48","date_gmt":"2026-06-04T12:07:48","guid":{"rendered":"https:\/\/flcube.com\/?p=67335"},"modified":"2026-06-04T20:07:52","modified_gmt":"2026-06-04T12:07:52","slug":"ascidian-therapeutics-partners-with-eli-lilly-in-1-9-billion-rna-exon-editing-deal-for-monogenic-kidney-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67335","title":{"rendered":"Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Ascidian Therapeutics<\/strong>, a US-based biotechnology company pioneering <strong>RNA exon editing technology<\/strong>, announced a <strong>global research collaboration and licensing agreement<\/strong> with <strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) to discover and develop therapies targeting <strong>undisclosed monogenic kidney diseases<\/strong>. The deal includes an option to expand to additional targets and provides Lilly with exclusive, target-specific rights to Ascidian&#8217;s proprietary platform.<\/p>\n\n\n\n<h2 id=\"h-transaction-structure-amp-financial-terms\" class=\"wp-block-heading\">Transaction Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>Ascidian Therapeutics + Eli Lilly (NYSE: LLY)<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Undisclosed monogenic kidney diseases<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>RNA exon editing<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>Up to $1.9 billion<\/td><\/tr><tr><td><strong>Payment Structure<\/strong><\/td><td>Upfront payment + development milestones + commercial milestones + tiered royalties<\/td><\/tr><tr><td><strong>Royalty Basis<\/strong><\/td><td>Global net sales<\/td><\/tr><tr><td><strong>Expansion Rights<\/strong><\/td><td>Option to add additional kidney disease targets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The substantial financial commitment underscores Lilly&#8217;s confidence in Ascidian&#8217;s RNA exon editing platform and the significant unmet medical need in monogenic kidney disorders.<\/p>\n\n\n\n<h2 id=\"h-development-amp-commercial-responsibilities\" class=\"wp-block-heading\">Development &amp; Commercial Responsibilities<\/h2>\n\n\n\n<h3 id=\"h-ascidian-therapeutics-role\" class=\"wp-block-heading\">Ascidian Therapeutics Role<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Lead early discovery activities<\/li>\n\n\n\n<li>Conduct certain preclinical studies<\/li>\n\n\n\n<li>Retain rights to independently or jointly develop other kidney targets with additional partners<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-eli-lilly-responsibilities\" class=\"wp-block-heading\">Eli Lilly Responsibilities<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Subsequent preclinical development<\/li>\n\n\n\n<li>Clinical trial execution and regulatory strategy<\/li>\n\n\n\n<li>Manufacturing scale-up and supply chain management<\/li>\n\n\n\n<li>Global commercialization and market access<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This division of labor leverages Ascidian&#8217;s expertise in RNA biology and platform innovation while utilizing Lilly&#8217;s established clinical development infrastructure and global commercial capabilities.<\/p>\n\n\n\n<h2 id=\"h-technology-platform-amp-scientific-rationale\" class=\"wp-block-heading\">Technology Platform &amp; Scientific Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>RNA Exon Editing:<\/strong> Novel approach that modifies RNA splicing to correct genetic defects at the transcript level<\/li>\n\n\n\n<li><strong>Monogenic Kidney Diseases:<\/strong> Rare inherited disorders caused by single gene mutations affecting kidney function<\/li>\n\n\n\n<li><strong>Therapeutic Advantage:<\/strong> Potential to address root cause rather than symptomatic management<\/li>\n\n\n\n<li><strong>Platform Flexibility:<\/strong> Technology can be adapted to multiple genetic targets within the kidney disease space<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The collaboration represents one of the first major partnerships focused specifically on RNA exon editing for renal indications, positioning both companies at the forefront of genetic medicine for kidney disorders.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications-amp-market-context\" class=\"wp-block-heading\">Strategic Implications &amp; Market Context<\/h2>\n\n\n\n<h3 id=\"h-for-ascidian-therapeutics\" class=\"wp-block-heading\">For Ascidian Therapeutics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Validation:<\/strong> Major pharmaceutical partnership validates platform technology<\/li>\n\n\n\n<li><strong>Financial Security:<\/strong> Significant upfront and milestone payments de-risk development pipeline<\/li>\n\n\n\n<li><strong>Strategic Flexibility:<\/strong> Retains ability to pursue other kidney targets with different partners<\/li>\n\n\n\n<li><strong>Resource Optimization:<\/strong> Focuses internal resources on core platform development<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-for-eli-lilly\" class=\"wp-block-heading\">For Eli Lilly<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Diversification:<\/strong> Expands genetic medicine portfolio beyond current focus areas<\/li>\n\n\n\n<li><strong>Technology Access:<\/strong> Gains exclusive rights to cutting-edge RNA exon editing platform for specific targets<\/li>\n\n\n\n<li><strong>Rare Disease Strategy:<\/strong> Strengthens position in orphan drug market with high-value pricing potential<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Addresses growing interest from other large pharma companies in RNA-based therapeutics<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-market-opportunity\" class=\"wp-block-heading\">Market Opportunity<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Monogenic Kidney Diseases:<\/strong> Collectively affect hundreds of thousands of patients globally<\/li>\n\n\n\n<li><strong>Treatment Gap:<\/strong> Most currently lack disease-modifying therapies<\/li>\n\n\n\n<li><strong>Orphan Drug Economics:<\/strong> High pricing potential with accelerated regulatory pathways<\/li>\n\n\n\n<li><strong>Platform Value:<\/strong> Success in initial targets could support expansion to broader kidney disease applications<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-innovation-context\" class=\"wp-block-heading\">Competitive Landscape &amp; Innovation Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The deal highlights the increasing competition among large pharmaceutical companies to secure access to next-generation RNA technologies, following the success of mRNA vaccines and antisense oligonucleotide therapies. Ascidian&#8217;s exon editing approach represents a distinct mechanism compared to traditional gene therapy or CRISPR-based DNA editing, potentially offering improved safety profiles and reversible effects.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding deal execution, development timelines, and commercial potential. Actual results may differ materially due to scientific challenges, regulatory outcomes, competitive developments, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ascidian Therapeutics, a US-based biotechnology company pioneering RNA exon editing technology, announced a global research&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4771,199,66,911],"class_list":["post-67335","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ascidian-therapeutics","tag-eli-lilly","tag-gene-therapy","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ascidian Therapeutics, a US-based biotechnology company pioneering RNA exon editing technology, announced a global research collaboration and licensing agreement with Eli Lilly and Company (NYSE: LLY) to discover and develop therapies targeting undisclosed monogenic kidney diseases. The deal includes an option to expand to additional targets and provides Lilly with exclusive, target-specific rights to Ascidian&#039;s proprietary platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67335\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases\" \/>\n<meta property=\"og:description\" content=\"Ascidian Therapeutics, a US-based biotechnology company pioneering RNA exon editing technology, announced a global research collaboration and licensing agreement with Eli Lilly and Company (NYSE: LLY) to discover and develop therapies targeting undisclosed monogenic kidney diseases. The deal includes an option to expand to additional targets and provides Lilly with exclusive, target-specific rights to Ascidian&#039;s proprietary platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67335\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-04T12:07:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-04T12:07:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67335#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67335\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases\",\"datePublished\":\"2026-06-04T12:07:48+00:00\",\"dateModified\":\"2026-06-04T12:07:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67335\"},\"wordCount\":560,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ascidian Therapeutics\",\"Eli Lilly\",\"Gene therapy\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67335#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67335\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67335\",\"name\":\"Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-04T12:07:48+00:00\",\"dateModified\":\"2026-06-04T12:07:52+00:00\",\"description\":\"Ascidian Therapeutics, a US-based biotechnology company pioneering RNA exon editing technology, announced a global research collaboration and licensing agreement with Eli Lilly and Company (NYSE: LLY) to discover and develop therapies targeting undisclosed monogenic kidney diseases. The deal includes an option to expand to additional targets and provides Lilly with exclusive, target-specific rights to Ascidian's proprietary platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67335#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67335\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67335#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"Ascidian Therapeutics, a US-based biotechnology company pioneering RNA exon editing technology, announced a global research collaboration and licensing agreement with Eli Lilly and Company (NYSE: LLY) to discover and develop therapies targeting undisclosed monogenic kidney diseases. The deal includes an option to expand to additional targets and provides Lilly with exclusive, target-specific rights to Ascidian's proprietary platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67335","og_locale":"en_US","og_type":"article","og_title":"Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases","og_description":"Ascidian Therapeutics, a US-based biotechnology company pioneering RNA exon editing technology, announced a global research collaboration and licensing agreement with Eli Lilly and Company (NYSE: LLY) to discover and develop therapies targeting undisclosed monogenic kidney diseases. The deal includes an option to expand to additional targets and provides Lilly with exclusive, target-specific rights to Ascidian's proprietary platform.","og_url":"https:\/\/flcube.com\/?p=67335","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-04T12:07:48+00:00","article_modified_time":"2026-06-04T12:07:52+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67335#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67335"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases","datePublished":"2026-06-04T12:07:48+00:00","dateModified":"2026-06-04T12:07:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67335"},"wordCount":560,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ascidian Therapeutics","Eli Lilly","Gene therapy","NYSE: LLY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67335#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67335","url":"https:\/\/flcube.com\/?p=67335","name":"Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-04T12:07:48+00:00","dateModified":"2026-06-04T12:07:52+00:00","description":"Ascidian Therapeutics, a US-based biotechnology company pioneering RNA exon editing technology, announced a global research collaboration and licensing agreement with Eli Lilly and Company (NYSE: LLY) to discover and develop therapies targeting undisclosed monogenic kidney diseases. The deal includes an option to expand to additional targets and provides Lilly with exclusive, target-specific rights to Ascidian's proprietary platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67335#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67335"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67335#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67335"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67335\/revisions"}],"predecessor-version":[{"id":67336,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67335\/revisions\/67336"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}